悦康藥業(688658.SH)：擬收購天龍藥業100%股權
格隆匯 2 月 5日丨悦康藥業(688658.SH)公佈，為實現公司在核酸藥物領域的佈局和發展，提升公司技術實力，公司與杭州天龍藥業有限公司(“天龍藥業”或“標的公司”)原股東杭州天龍集團有限公司、朱德領(“天龍藥業原股東”)於近期簽署《杭州天龍藥業有限公司股權轉讓協議》，公司以自有資金合計人民幣2100萬元收購天龍藥業原股東持有天龍藥業的100%股權，同時，承擔天龍藥業欠付原合作單位900萬元CT102項目進度款的付款義務。根據中水致遠資產評估有限公司出具的中水致遠評報字[2021]第020064號《評估報吿》，天龍藥業經評估後淨資產為2113.42萬元。此次交易完成後，公司將持有天龍藥業100%股權。
天龍藥業擁有國家發展和改革委員會批覆的核酸藥物領域首個核酸藥物國家地方聯合工程研究中心，是中國核酸產學研聯盟骨幹單位、浙江省核酸藥物工程中心、浙江省科技型中小企業和杭州市雛鷹企業。天龍藥業主要從事核酸藥物的研究與開發，其化學藥品1類新藥CT102（“CT102”）系我國首個完全自主研發的反義核酸（ASO）藥物，凍幹劑型，用於原發性肝細胞癌的治療，2018年3月獲得國家藥品監督管理局下發的《藥物臨牀試驗批件》，目前正在準備進行I期臨牀研究。同時，標的公司亦儲備了其它核酸藥物候選品種，但尚處於不同的臨牀前研發階段。
公司抗腫瘤小分子創新化藥“硫酸氫烏莫司他膠囊”正處於臨牀I期研究階段。抗腫瘤是核酸藥物臨牀開發的主要適應症之一，通過此次收購，取得CT102《藥物臨牀試驗批件》，豐富了公司的腫瘤用藥管線，同時，CT102為凍幹劑型，與公司的凍幹生產線契合度很高，公司的生產技術能夠滿足未來生產需求並提高公司的產能利用率。
此次收購完成後，公司將在標的公司研發團隊及與原合作單位合作的基礎上，加快核酸藥物領域研發人員的引進，擴大核酸藥物研發團隊的規模，加強與國內核酸藥物領域專家合作，積極探討立項新的核酸藥物研發項目，同時，購置先進的核酸研發設備，打造和完善核酸藥物研發平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
